Compositions useful for and methods of modulating angiogenesis
Compositions and methods for treating subjects with disorders characterized by aberrant vascular endothelial cell growth are provided. The compositions comprise agents that are combinations of a Wnt pathway stimulator component and a Tie2 pathway repressor component. Particularly useful Wnt pathway stimulators include, but are not limited to, Wnt7b-like molecules. Particularly useful Tie2 pathway repressor components include, but are not limited to, Ang2-like molecules. The methods allow for modulation of vascular endothelial cells, vascular endothelial cell vessels, capillary bed development, and angiogenesis.
1. A vascular endothelial cell vessel modulating compound comprising a Wnt pathway stimulator and a Tie2 pathway repressor.
2. The compound of claim 1 , wherein the Wnt pathway stimulator is a Wnt7b-like molecule.
3. The compound of claim 2 , wherein said Wnt7b-like molecule is a Wnt7b molecule selected from the group consisting of:
(a) an isolated polypeptide having an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID:5, or SEQ ID NO:6; and
(b) an isolated polypeptide having an amino acid sequence having at least 95% identity to an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID:5, or SEQ ID NO:6, wherein said polypeptide is capable of interacting with a Fzd4 receptor.
4. The compound of claim 1 , wherein the Tie2 pathway repressor is an Ang2-like molecule.
5. The compound of claim 4 , wherein said Ang2-1 like molecule is an Ang2 molecule selected from the group consisting of:
(a) an isolated polypeptide having an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID:I 1, or SEQ ID NO:12; and
(b) an isolated polypeptide having an amino acid sequence having at least 95% identity to an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID:I 1, or SEQ ID NO: 12, wherein said polypeptide is capable of interacting with Tie2.
6. The compound of claim 1 , wherein the Wnt pathway stimulator is a Wnt7b-like molecule and wherein the Tie2 pathway repressor is an Ang2-1 like molecule.
7. A vascular endothelial cell vessel modulating compound comprising a Wnt pathway stimulator and a Tie2 pathway repressor, wherein said Wnt pathway stimulator is a Wnt7b-like molecule and wherein the Tie2 pathway repressor is an Ang2-like molecule.
8. A method of regressing angiogenesis in a subject in need thereof, said method comprising the step of administering to the subject a compound of claim 1 , wherein angiogenesis regresses.
9. A method of regressing a vascular endothelial cell vessel in a subject in need thereof, said method comprising the step of administering a compound of claim 1 , wherein said vascular endothelial cell vessel regresses.
10. A method of regressing angiogenesis in a subject in need thereof, said method comprising the step of administering to the subject a compound of claim 7 , wherein said angiogenesis regresses.
11. The method of claim 10 further comprising the step of evaluating the regression of a vascular endothelial cell vessel subsequent to the administration of said compound.
12. A method of producing apoptosis of a vascular endothelial cell in a subject in need thereof, said method comprising the step of administering to the subject a compound of claim 7 , wherein said vascular endothelial cell undergoes apoptosis.
13. A method of regressing a vascular endothelial cell vessel in a subject in need thereof, said method comprising the step of administering a vascular endothelial cell vessel modulating compound comprising a Wnt pathway stimulator and a Tie2 pathway repressor, wherein said Wnt pathway stimulator is a Wnt7b-like molecule and wherein the Tie2 pathway repressor is an Ang2-like molecule, wherein said vascular endothelial cell vessel regresses.
14. The method of claim 13 , wherein a vascular endothelial cell of said vascular endothelial cell vessel undergoes apoptosis.
15. A method of treating an angiogenic-related disorder comprising the steps of:
(a) identifying a subject exhibiting an angiogenic-related disorder; and
(b) administering a therapeutically effective amount of a compound comprising a Wnt pathway stimulator and a Tie2 pathway repressor to said subject, wherein the angiogenic-related disorder is treated.
16. The method of claim 15 , wherein said angiogenic-related disorder is selected from the group consisting of ocular angiogenic disorders and hyperproliferative disorders.
17. The method of claim 15 , wherein said Wnt pathway stimulator is a Wnt7b-like molecule and wherein the Tie2 pathway repressor is an Ang2-1 like molecule.
18. The method of claim 17 , wherein said Wnt7b-like molecule is a Wnt7b molecule selected from the group consisting of:
(a) an isolated polypeptide having an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID:5, or SEQ ID NO:6; and
(b) an isolated polypeptide having an amino acid sequence having at least 95% identity to an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID:5, or SEQ ID NO:6, wherein said polypeptide is capable of interacting with a Fzd4 receptor.
19. The method of claim 17 , wherein said Ang2-like molecule is an Ang2 molecule selected from the group consisting of:
(a) an isolated polypeptide having an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID:I 1, or SEQ ID NO:12; and
(b) an isolated polypeptide having an amino acid sequence having at least 95% identity to an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID:I 1, or SEQ ID NO: 12, wherein said polypeptide is capable of interacting with Tie2.
20. The method of claim 15 , wherein said angiogenic-related disorder is a vascular endothelial cell vessel-related disorder.
21. The method of claim 20 , wherein a vascular endothelial cell vessel regresses.
22. The method of claim 20 , wherein a vascular endothelial cell undergoes apoptosis.
23. A method of regressing capillary bed development comprising the steps of:
(a) providing a subject in need of capillary bed development regression; and
(b) administering a vascular endothelial cell vessel regressing compound comprising a Wnt pathway stimulator and a Tie2 pathway repressor to a subject, wherein said capillary bed development regresses.